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A BS TR AC T
BACKGROUND
Vitamin B12 (cobalamin) is an essential cofactor in several metabolic pathways. Intra-
cellular conversion of cobalamin to its two coenzymes, adenosylcobalamin in mi-
tochondria and methylcobalamin in the cytoplasm, is necessary for the homeosta-
sis of methylmalonic acid and homocysteine. Nine defects of intracellular cobalamin 
metabolism have been defined by means of somatic complementation analysis. One 
of these defects, the cblD defect, can cause isolated methylmalonic aciduria, isolated 
homocystinuria, or both. Affected persons present with multisystem clinical abnor-
malities, including developmental, hematologic, neurologic, and metabolic findings. 
The gene responsible for the cblD defect has not been identified.
METHODS
We studied seven patients with the cblD defect, and skin fibroblasts from each were 
investigated in cell culture. Microcell-mediated chromosome transfer and refined 
genetic mapping were used to localize the responsible gene. This gene was trans-
fected into cblD fibroblasts to test for the rescue of adenosylcobalamin and meth-
ylcobalamin synthesis.
RESULTS
The cblD gene was localized to human chromosome 2q23.2, and a candidate gene, 
designated MMADHC (methylmalonic aciduria, cblD type, and homocystinuria), was 
identified in this region. Transfection of wild-type MMADHC rescued the cellular 
phenotype, and the functional importance of mutant alleles was shown by means 
of transfection with mutant constructs. The predicted MMADHC protein has se-
quence homology with a bacterial ATP-binding cassette transporter and contains a 
putative cobalamin binding motif and a putative mitochondrial targeting sequence.
CONCLUSIONS
Mutations in a gene we designated MMADHC are responsible for the cblD defect in 
vitamin B12 metabolism. Various mutations are associated with each of the three 
biochemical phenotypes of the disorder.
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Vitamin b12 (cobalamin) is essential for normal development and survival in hu-mans and must be obtained from animal 
products or supplements. Inside the cell, it is con-
verted to two active cofactors, adenosylcobalamin 
and methylcobalamin (Fig. 1).1 Adenosylcobalamin 
is the coenzyme for mitochondrial methylmalo-
nyl–coenzyme A mutase, which converts l-methyl-
malonyl–coenzyme A to succinyl–coenzyme A and 
is involved in catabolism of odd-chain fatty acids 
and some amino acids. Methylcobalamin is the co-
enzyme for cytosolic methionine synthase, which 
converts homocysteine to methionine and is essen-
tial for normal one-carbon metabolism, which is 
in turn involved in vital cellular processes such 
as methylation and DNA synthesis.1 Disturbanc-
es of cobalamin-cofactor synthesis due to acquired 
or inherited alterations result in elevated levels of 
homocysteine and methylmalonic acid, which are 
associated with multisystem clinical abnormali-
ties similar to those seen in patients with severe 
nutritional vitamin B12 deficiency, including leth-
argy, hypotonia, developmental delay, seizures, and 
megaloblastic anemia.
Inborn errors of cobalamin-cofactor synthesis 
represent a heterogeneous and important group 
of rare disorders. Intracellular cobalamin metab-
olism involves multiple steps between the lyso-
somal release of cobalamin and the synthesis of 
adenosylcobalamin in the mitochondria and meth-
ylcobalamin in the cytosol. To date, nine distinct 
defects of this pathway have been defined in vitro 
with the use of somatic complementation analy-
sis. The complementation groups thus identified 
have been designated cblA, cblB, cblC, cblD, cblE, 
cblF, cblG, cblH, and mut (Fig. 1).2,3 The respon-
sible genes are known except for cblD, cblF, and 
cblH, although the function of some of the associ-
ated proteins is not clear. The cblC and cblF dis-
orders cause combined homocystinuria and methyl-
malonic aciduria; cblA, cblB, cblH, and mut cause 
isolated methylmalonic aciduria; and cblE and 
cblG cause isolated homocystinuria. The cblD de-
fect (Online Mendelian Inheritance in Man num-
ber, 277410)2 is puzzling in that some patients 
have combined methylmalonic aciduria and ho-
mocystinuria (called “cblD original” by Suormala 
et al.2 but herein called “cblD-combined”), some 
have only isolated homocystinuria (called “cblD-
variant 1”2 or, herein, “cblD-homocystinuria”), and 
others have only methylmalonic aciduria (“cblD-
variant 2”2 or, herein, “cblD–methylmalonic acid-
uria”). Here, we describe our identification of the 
cblD gene, confirmation of its identity by using 
biochemical and molecular studies, and demon-
stration of functionally significant mutations in 
patients with the cblD defect.
Me thods
PATIENTS AND CELL LINES
The study was performed between 2004 and 2007. 
Seven unrelated patients with the cblD defect were 
studied. Written informed consent was obtained 
from the parents of each patient, and patients who 
could give assent did so. The study was approved 
by the local ethics committee.
Cultures of skin fibroblasts were obtained for 
diagnostic purposes, and referring physicians 
approved the use of the samples for our investi-
gation of the origin of the disease. We immortal-
ized fibroblasts using the plasmid pRNS14 and 
electroporation (Gene Pulser II, BioRad). Immor-
talization did not markedly affect cellular function 
(data not shown).
The functional integrity of the methylmalonic-
acid pathway was evaluated by measuring the de-
gree of incorporation of [14C]propionate into mac-
romolecules and formation of adenosylcobalamin 
from [57Co]cyanocobalamin, as described previ-
ously.2 The integrity of methionine synthase in the 
homocysteine pathway was defined as the forma-
tion of methionine from [14C]formate and synthe-
sis of methylcobalamin from [57Co]cyanocoba-
lamin.2
Somatic complementation analysis2 confirmed 
that all fibroblast cell lines from patients belonged 
to the cblD group (including one that had been 
used to define cblD5). A fibroblast cell line from 
one of the seven patients had previously been as-
signed to a new complement group (cblH) by 
Watkins et al.,6 but we show here that it in fact 
belongs to the cblD complement group (Fig. 1 in 
the Supplementary Appendix, available with the 
full text of this article at www.nejm.org).
MICROCELL-MEDIATED CHROMOSOME TRANSFER
Mouse–human monochromosomal hybrid cell 
lines (donor cells), each carrying a single human 
chromosome tagged with a hygromycin resistance 
gene,7 were used to serially transfect one of the 
immortalized cblD-homocystinuria cell lines (re-
cipient cells) with the use of microcell-mediated 
chromosome transfer, as described previously8 
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(also see Table 1 in the Supplementary Appendix). 
Cells containing each transfected human chro-
mosome were selected on the basis of growth in 
medium containing hygromycin. Colonies were 
subcultured and assayed for methylcobalamin syn-
thesis. Those that showed such synthesis, and thus 
the rescue of cellular function, were defined as 
positive colonies; those that did not were defined 
as negative colonies.
GENE MAPPING
Positive colonies were tested for contamination 
by mouse DNA with the use of the mouse-spe-
cific microsatellite markers BAM5 and RSINE1 
SINE/B4.9,10 Positive colonies that were free of 
mouse DNA contamination and negative colonies 
then were used in the fine mapping of the donor 
chromosome, by means of microsatellite markers, 
to define the chromosomal segment containing the 
putative gene corresponding to the cblD defect. 
The presence of these microsatellite markers was 
tested with the use of the polymerase-chain-reac-
tion (PCR) assay, involving fluorescently labeled 
primers. Products were visualized in an automat-
ed sequencer (ABI Prism 3100, Applied Biosystems) 
and analyzed with Genotyper software (version 2.5, 
Applied Biosystems). The chromosomal region de-
fined by the microsatellite markers was examined 
for candidate genes, and a suitable candidate was 
selected on the basis of sequence characteristics.
DNA SEQUENCING AND MUTATION ANALYSIS
Total RNA was extracted from cultured fibro-
blasts with the use of the RNeasy Kit (Qiagen), and 
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Figure 1. Intracellular Cobalamin Metabolism and Its Defects.
To date, nine complementation-group defects of the cobalamin pathway have been described. Cobalamin bound to 
transcobalamin enters the cell by means of lysosome-mediated endocytosis and is released t rough proteolysis. Ex-
port from the lysosome into the cytoplasm is defective in patients with the cblF defect. The steps in the cytosol af-
ter lysosomal release are still unclear but are defined by the complementation groups cblC and cblD. In addition, 
the exact form of cobalamin at this stage is unclear (as indicated by “Cblx”). In the cytoplasm, cobalamin is reduc-
tively methylated by methionine synthase reductase (cblE) to methylcobalamin, the cofactor for methi nine syn-
thase (cblG). After its transport into the mitochondrion, cobalamin is converted to adenosylcobalamin, the cofactor 
for methylmalonyl–coenzyme A (CoA) mutase (mut), by cobalamin adenosyltransferase (cblB). The exact role of the 
protein associated with the cblA complementation group is unclear. Our studies show that the cblD protein consti-
tutes a branch point between the cytosolic and mitochondrial pathways, controlled by the cblD–methylmalonic ac-
iduria variant and the cblD-homocystinuria variant, respectively. We also show that the cblH complementation 
group is identical to the cblD–methylmalonic aciduria group.
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full-length complementary DNA (cDNA) for the 
candidate gene was amplified by means of a re-
verse-transcriptase PCR (RT-PCR) assay involving 
specific primers and was sequenced according to 
the ABI BigDye method (Applied Biosystems). To 
confirm mutations identified in the RT-PCR prod-
ucts, the corresponding exons were amplified 
through the PCR assay from genomic DNA, with 
the use of flanking intronic primers, and were se-
quenced.
EXPRESSION OF CANDIDATE GENE cDNA  
IN FIBROBLASTS
Constructs containing wild-type and mutant cDNA 
sequences for the candidate gene were prepared 
in pTracer-CMV2 or pcDNA3.2/V5 expression vec-
tors (Invitrogen), as described previously.11 Con-
structs were transfected into immortalized fibro-
blasts by means of electroporation. Transfection 
efficiency was 5 to 22%, as determined by esti-
mating the proportion of cells coexpressing the 
green fluorescent protein from the pTracer con-
struct. Rescue of cellular function was tested by 
measuring methionine and methylcobalamin syn-
thesis or adenosylcobalamin synthesis.
STATISTICAL Analysis
We tested the statistical significance of the data on 
rescue of function by using the unpaired t-test (two-
tailed), with Welch’s correction for unequal vari-
ances, and GraphPad Prism software (version 4). 
P values less than 0.05 were considered to indicate 
statistical significance.
R esult s
CLINICAL DATA
The clinical features of the seven patients are shown 
in Table 1. Two patients had the isolated homocys-
tinuria phenotype, and two had the isolated methyl-
malonic aciduria phenotype. These four patients 
have been described previously (Table 1). The three 
other patients, two of whom are newly described 
in this study, had the combined phenotype (methyl-
malonic aciduria and homocystinuria).
GENE LOCALIZATION
To identify the chromosome containing the cblD 
gene, we transfected immortalized cblD-homocys-
tinuria cells (from Patient 2) with individual human 
chromosomes contained in mouse–human single-
chromosome hybrid cell lines using microcell-
mediated chromosome transfer. We then tested 
the resulting cell lines for rescue of function by 
measuring methylcobalamin synthesis. Transfec-
tion with chromosome 2 yielded 48 colonies that 
showed correction of methylcobalamin synthesis 
(positive colonies) and 24 colonies that did not 
(negative colonies) (Table 1 in the Supplementary 
Appendix). The positive colonies were screened for 
mouse-specific sequences, and four were found to 
be free of contamination with mouse DNA.
A panel of 38 microsatellite markers spanning 
chromosome 2 was used to perform fine mapping 
of the chromosome fragments from the 4 positive 
colonies and 22 of the negative colonies (see Ta-
ble 2 in the Supplementary Appendix). This fine-
mapping procedure identified a 10.2-Mb DNA 
segment between markers D2S150 and D2S2324 
that was present in DNA from positive colonies 
but absent in all the negative colonies (Fig. 2 in the 
Supplementary Appendix). This mapped the cblD 
gene to the chromosome region 2q22.1–2q23.3 
(Fig. 2A), which contains 28 genes (according to 
the deCODE genetic map; for details, see the ac-
cession numbers and URLs in Note 1 in the Sup-
plementary Appendix). The C2orf25 gene was se-
lected as a candidate because of its homology14 
to a putative mitochondrial ATPase component 
of a bacterial ATP-binding cassette (ABC) trans-
porter (YP_218380) and because cobalamin 
transport in bacteria is facilitated by an ABC 
transport system.15
MUTATION ANALYSIS
The full-length cDNA for the candidate gene 
C2orf25 was amplified by means of RT-PCR and 
specific primers (Table 3 in the Supplementary Ap-
pendix). The C2orf25 gene was then sequenced from 
cDNA from each of the seven patients with the 
cblD defect, and mutations for each patient were 
identified. These mutations were further confirmed 
with the use of PCR amplification of the appro-
priate exons from genomic DNA, involving flank-
ing intronic primers (Table 3 in the Supplemen-
tary Appendix). We identified nine mutations, with 
two mutant alleles in each patient (Table 1 and 
Fig. 2B).
Five of the mutations we identified are pre-
dicted to lead to a premature stop codon, result-
ing in a truncated protein: two nonsense muta-
tions (160C→T, 748C→T), two deletions (57_64del, 
696+1_4del), and one duplication (419dupA). The 
696+1_4del splice-site mutation was shown by 
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means of RT-PCR to cause the skipping of exon 7. 
This mutation was present in the homozygous 
state in Patient 7 and was found in the heterozy-
gous state in both parents and in an at-risk fetus 
in this family (data not shown).
One in-frame duplication (307_324dup) was 
identified. This mutation is predicted to add six 
amino acids to the protein product.
Three mutations causing a single amino acid 
change were found (545C→A, 746A→G, and 
776T→C), each occurring in a region of the gene 
that is highly conserved among species (Fig. 3). 
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Figure 2. Location, Structural Organization, and Mutations of MMADHC (Methylmalonic Aciduria, cblD Type,  
and Homocystinuria).
Panel A shows the fragment of chromosome 2, between markers D2S150 and D2S2324, that was identified by 
means of microcell-mediated chromosome transfer and microsatellite mapping. This fragment is 10.2 Mb in length. 
The position of the markers is indicated according to the National Center for Biotechnology Information’s human 
reference sequence, build 36.1. MMADHC (currently named C2orf25; locus NM_015702) is located in chromosome 
2 (genomic sequence NT_005403) and maps to chromosome region 2q23.2. The gene consists of eight exons. 
Three in-frame stop codons precede the first initiation codon (ATG) in exon 2. Exon 1 and the 5′ end of exon 2 are 
not translated. Exons 2 through 8 encode an 891-bp message, from the initiation codon to the TAG termination co-
don, predicted to encode a polypeptide of 296 ami o acids with a predict d molecular mass of 32.8 kD. The coding 
regions are indicated as black vertical bars with exon numbers above and the size in base pairs below; intron sizes, 
in base pairs, are indicated between the exons. Panel B represents composite complementary DNA (cDNA) for 
MMADHC and shows the location of mutations, grouped according to the cblD phenotype. Exons are represented 
by the numbered boxes, and the numbers below the boxes indicate the position within the cDNA sequence of the 
last nucleotide of each exon.
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These three missense mutations occurred in pa-
tients of European origin and did not occur in 
100 control chromosomes from subjects with the 
same ethnic backgrounds, substantially reducing 
the likelihood that these are common polymor-
phisms. Parental DNA, used to rule out a deletion 
in the homozygous patients, was available from 
only one family.
TISSUE EXPRESSION AND PROTEIN 
CHARACTERIZATION
We searched databases of known expressed se-
quences of the human genome to ascertain the tis-
sue expression of the C2orf25 gene. This gene ap-
pears to be expressed at high levels in most tissues 
(Note 2 in the Supplementary Appendix). To de-
tect possible multiple transcripts, we amplified 
C2orf25 from fibroblast messenger RNA (mRNA), 
by using RT-PCR and various primers. We found 
only a single cDNA product, with a coding region 
of 891 bp, encoding a putative polypeptide of 296 
amino acids and a predicted molecular weight of 
32.8 kD (Fig. 3). Residues 1 through 12 constitute 
a possible mitochondrial leader sequence, which 
suggests targeting of the expressed protein to mi-
tochondria.16 Residues 81 though 86 match the 
36p6
H.sapiens LAEPLSSERHEFVMAQYVNEFQGNDAPVEQ-EINSAETYFESARVECAIQTCPELLRKDFESLFPEVANGKL---MILTVTQKTKNDMTVWSEEVEIEREVL 200
P.troglodytes LAEPLSSERHEFVMAQYVNEFQGNDAPVEQ-EINSAETYFESARVECAIQTCPELLRKDFESLFPEVANGKL---MILTVTQKTKNDMTVWSEEVEIEREVL 200
B.taurus LAEPLSSERHEFVMAQYVNEFQGNDAPVEQ-EINSAETYFESAKVECAIQTCPELLRRDFESLFPEVATNKL---MILTVTQKTKNDMTVWSEEVENEREVL 200
C.familiaris LAEPLSSERHEFVMAQYVNEFQGNNAPVEQ-EISSAETYFENAKVECAIQTCPELLRRDFESLFPEGATNKL---MILTITQKTKNDMTVWSEEVENEREML 200
M.musculus LAEPLSTERHEFVMAQYVNEFQDSDAPVEQ-EINSAETYFESAKVECAIQTCPELLRRDFESLFPEVANSKL---MILTVTQKTENDMTVWSEEVEVEREVL 200
R.norvegicus LAEPLSTERHEFVMAQYVNEFQDSNAPVEQ-EISSAETYFESARVECAIQTCPELLRRDFESLFPEVANSKL---MILTVTQKTEHDMTVWSEEVEVEREAL 197
O.cuniculus LAEPLSSERHEFVMAQYVNEFQGHNTPVEQ-EINSAETYFESARVECAIQTCPELLRRDFESLFPEMSNSKL---MILTVTQKTQNDMTVWSEEVETEREML 200
M.domesticus LAEPLSSERHEFVMAQYVNEFEGSDVPVEQQEVNKAETYFENAKVECVLQTCPELLRKDFESIFPEVNSGKL---MVLTVTQKTKNDMTTWSEEVENEREML 198
G.gallus LAEPSPNERHEFVMAQYINEFQGSDVPQKQ-QVNNAETYFENAKVECAVQACPELLRKDFESMFPEVNANHL---TVLTVTQKTKNDMTVWSQEVEDEREML 200
D.rerio LTAQSNNQRHDFILAQFINELHEDDKTSTAQNMDKAEQFFDHSSVECAIQSCPELLKRDFESMFPEAPSTGM---MVVTVTQRTQNDMTAWTEQVDQEREEL 199
C.elegans VMDDTEHNLINLLSNTNIEVDRTHLAQLKEEAMEEIQANAADVEIELSAIEAPKLLKKEMKYLFPQMETQKMNNVTVFNLTQKSEFDMKAWSEAMEEEREKL 180
H.sapiens LEKFINGAKEICYALRAEGYWADFIDPSSGLAFFGPYTNNTLFETDERYRHLGFSVDDLGCCKVIRHSLWGTHVVVGSIFTNATPD----SHIMKKLSGN--- 296
P.troglodytes LEKFINGAKEICYALRAEGYWADFIDPSSGLAFFGPYTNNTLFETDERYRHLGFSVDDLGCCKVIRHSLWGTHVVVGSIFTNATPD----SHIMKKLSGN--- 296
B.taurus LEKFISGAKEICYALRAEGYWADFIDPSSGLAFFGPYTNNTLFETDERYRHLGFSVDDLGCCKVIRHSLWGTHVVVGSIFTNATPD----SHIMKKLSGN--- 296
C.familiaris LEKFINGAKEICYALRAEGYWADFIDPSSGLAFFGPYTNNTLFETDERYRHLGFSVDDLGCCKVIRHRLWGTHVVVGSIFTNATPD----SHIMKKLGGNQQ- 298
M.musculus LEKFISGAKEICYALRAEGYWADFIDPSSGVAFFGPYTNNTLFETDERYRHLGFSVDDLGCCKVIRHSLWGTHVVVGSIFTNATAD----SSIMRKLSGN--- 296
R.norvegicus LEKFINGAKEICYALRAEGYWADFIDPSSGLAFFGPYTNNTLFETDERYRHLGFSVDDLGCCKVIRHGLWGTHVVVGSIFTNATAD----SHIMRKLSGD--- 293
O.cuniculus LEKFISGAKEICYALRAEGYWADFIDPSSGLAFFGPYTNNTLFETDERYRHLGFSVDDLGCCKVIRHSLWGTHVFVGSIFTNATPD----SHIMKKLSGN--- 296
M.domesticus LEKFITGAKEICYALRTEGYWADFIDPSSGLAFFGPYTSNTLFETDERYRHLGFSVDDLGCCKVIRHSIWGTHVVVGSIFTNATPD----SRIMKKLSGN--- 294
G.gallus LENFINGAKEICYAICSEGYWADFIDPSSGLAFFGPYTNNTLFETDERYRHFGFSVDDLGCCKVIRHNIWGTHVVVGSIFTNAEPD----SPIMRKLSGN--- 296
D.rerio LAKFIEGAKEICHALRNEGFWADFIDPSSGLAYFGSYTNNTLFETDDRYRHLGFQIEDLGCCKVIRHVMWGTHAFVGTLFTSAPPN----SQIMKKLQGDLS- 297
C.elegans TASFIMSANAICSTLHRFGYWADFIDPSSGRPYMGDYTNHTLFETNDAYKQMGFKIEDLGCCKVLQHACWGSNAFVGTIFTDAPVDGDAVRDILKKVTQEDIE 283
MLS Bacterial ABC Transporter
Thr182→AsnTyr140XLeu103_Ser108dup
Phe204_Ala232del
H.sapiens MANVLCNRARLVSYLPGFCSLVKRVVNPKAFSTAGSSGSDESHVAAAPPDICSRTVWPDETMGPFGPQDQRFQLPGNIGFDCHLNGTASQKKSLVHKTLPDV 102
P.troglodytes MANVLCNRARLVSYLPGFCSLVKRVVNPKAFSTAGSSGSDESHVAAAPPDICSRTVWPDETMGPFGPQDQRFQLPGNIGFDCHLNGTASQKKSLVHKTLPDV 102
B.taurus MANVLCNRARLISYLPGFCSLVKRVVNPRAFSTAGSSGSDESHVATAPPDICSRTVWPDETMGPFGPQDQRFQLPGNIGFDCHLNGTASQKKSQVHKTLPDV 102
C.familiaris MATVLCNRARLVSYVPGFCSLVKRVVSPKAFSTAGSSGSDESHVATAPPDICSRTVWPDETMGPFGPQDQRFQLPGNIGFDCHLNGTTSQKKSQLHKTLPDV 102
M.musculus MAHVLCNRARLVSYLPGFCSLVKRVINPRAFSTAGSSGSDESHVATAPPDICSRTVWPDETMGPFGPQDQRFQLPGNIGFDCHLNGTASQKKSQAHKTLPDV 102
R.norvegicus ---VLCNRARLVSYLPGFCSLVKRVINPRAFSTAGSSGSDESHVATAPPDICSRTVWPDETMGPFGPQDQRFQLPGNIGFDCHLNGTASQKKSQAHKTLPDV   99
O.cuniculus MANVLCNRARLVSYLPGFCSLVKRVVNPRAFSTAGSSGSDESHVATAPPDICTRTVWPDEAMGPFGPQDQRFQLPGNIGFDCHLNGTASQKKNQVNKTLPDV
V
102
M.domesticus ---VLCSRARLVTYLPGFYSLVRRVVNPKAFSTAGSSGSDESHVATTPPDICSRTVWPDETMGPFGPQDQRFQLPGNIGFDCHLNGTALQKKNPVHRTLPD 99
G.gallus MANVLCNRARLVTYLPGFYSLVKRVVNPKAFSTAGSSGSDEPHVAATPPDLCPRTVWPDEVMGPFGPQDQRFQLPGNIGFDCHLNGTAAQRKSQASKSLPDI 102
D.rerio MASVLCSRARLVTYLPGLHVLVHRVVGARSFS--GASGSDEPHLNTSTPDIAPRTVWPDESMGPFGPQDKRFQLPGNVGFDCHLESPVEQRTTSVHSVMPDV 100
C.elegans -------------------MLSAKGPQMRAFTQRVAAFSTQLQIDPIPIVFVGKGTTPRQNS-LLGPNDSQYPFQGDVSFAHKP----LSIRQQvENSKIER   78
Cys19fsX20 Arg54X
Leu259→ProArg250XTyr249→Cys
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Figure 3. Evolutionary Conservation of MMADHC (Methylmalonic Aciduria, cblD Type, and Homocystinuria).
Amino acid sequence alignment for MMADHC and its orthologues was performed with the use of ClustalW software. Residues that are 
identical in all species listed are shown in black; residues with conservative substitutions are shown in gray. The portion of the sequence 
with genetic identity to a bacterial hypothetical mitochondrial ATP-binding cassette (ABC) transporter is indicated. The amino acids con-
stituting the putative cobalamin binding motif are underlined (residues 81–86). Dashes r present amino acids that are absent in the pro-
tein of the particular species. The value along the right side of the sequences indicates the number of the last amino acid shown in the 
row. MLS denotes the putative mitochondrial leader sequence, as predicted by means of the Mitoprot II program. Sequences are shown 
for the following species (top to bottom in each group): Homo sapiens, Pan troglodytes, Bos taurus, Canis familiaris, Mus musculus muscu-
lus, Rattus norvegicus, Oryctolagus cuniculus, Mus musculus domesticus, Gallus gallus, Danio rerio, and Caenorhabditis elegans.
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vitamin B12 binding motif, Asp–Xaa–His–Xaa–
Xaa–Gly, constituting a putative binding site for 
cobalamin.17
EXPRESSION OF HUMAN C2orf25 cDNA  
IN FIBROBLASTS
To prove that the C2orf25 gene is responsible for 
the cblD phenotype, we tested the ability of wild-
type and mutant constructs to rescue cellular func-
tion (Fig. 4). The wild-type construct rescued me-
thionine synthesis and methylcobalamin synthesis, 
which were both restored to 52 to 100% of the 
control values in both cblD-homocystinuria and 
cblD-combined fibroblasts with the use of the 
pTracer vector (Fig. 4A and 4B). Adenosylcobala-
min synthesis was not reproducibly corrected with 
the use of the pTracer wild-type construct. To test 
for rescue of adenosylcobalamin synthesis, we re-
peated the experiment with the DNA3.2/V5 vector 
containing the wild-type construct and showed 
restoration of adenosylcobalamin synthesis to 68% 
of the control value in a cblD-combined cell line 
(Fig. 4C).
Constructs containing the missense alleles as-
sociated with isolated homocystinuria (545C→A, 
746A→G, and 776T→C) did not restore methionine 
or methylcobalamin synthesis in either cblD-homo-
cystinuria or cblD-combined cells, confirming that 
these mutant alleles cause the homocystinuria 
phenotype (Fig. 4A and 4B). Both constructs con-
taining the mutations found in isolated methyl-
malonic aciduria (57_64del and 160C→T) rescued 
the synthesis of methylcobalamin (Fig. 4B).
Together, these findings suggest that mutations 
in the C2orf25 gene are responsible for the cblD 
defect. We have therefore designated the gene 
MMADHC, or methylmalonic aciduria, cblD type, 
and homocystinuria (to indicate either the isolat-
ed phenotype or the combined phenotype).
Discussion
We show evidence that mutations of the gene 
C2orf25, which we have designated MMADHC, cause 
the cblD defect in vitamin B12 metabolism. Our 
evidence includes the identification of nonconser-
vative mutations in MMADHC in each of seven pa-
tients with cblD defects and the demonstration 
that expression vectors containing the wild-type 
MMADHC gene rescue cblD function in fibroblast 
cell lines. The predicted MMADHC protein con-
tains the putative cobalamin binding motif and a 
putative mitochondrial targeting sequence.
A complete analysis of the cblD defect requires 
an explanation of how mutations in the candidate 
gene lead to three distinct biochemical pheno-
types. Although our data as described do not fully 
satisfy this requirement, our results suggest that 
the nature and location of the mutations are cor-
related with the biochemical phenotype, as il-
lustrated in Figure 2B. Mutations found in the 
patients with cblD–methylmalonic aciduria are 
located toward the N-terminal part of the protein 
and consist of a nonsense mutation, a duplication, 
and a frame-shift deletion. Mutations found in the 
patients with cblD-homocystinuria are located to-
ward the C-terminal part of the protein and con-
sist of three missense mutations. Mutations found 
in the patients with the cblD-combined pheno-
type are located toward the C-terminal part of 
the protein and consist of a nonsense mutation, 
a splice-site deletion, and a frame-shift dupli-
cation.
Explaining these associations fully will require 
further studies. However, we offer the following 
speculations. The two patients with the cblD–
methylmalonic aciduria defect carry mutations 
that are predicted to lead to truncated proteins of 
19 amino acids in length (57_64del) or 53 amino 
acids in length (160C→T). We propose that the 
Met62 codon acts as a second start codon and 
leads to the reinitiation of translation,18 resulting 
in the formation of a shorter functional cblD pro-
tein product that lacks the putative mitochondrial 
leader sequence but allows for normal methylco-
balamin synthesis. This would explain the iso-
lated methylmalonic aciduria without homocys-
tinuria in Patients 3 and 4 and is in accordance 
with the rescue of methionine and methylcobala-
min synthesis in cblD-homocystinuria and cblD-
combined cell lines transfected with the mutant 
alleles 57_64del and 160C→T. In support of this 
“reinitiation of translation” hypothesis, a strong 
Kozak consensus sequence19 occurs at cDNA po-
sitions 184−3 and 184+4 (A at position −3 and G 
at position +4) in the MMADHC gene.
Both patients with isolated homocystinuria 
carry missense mutations (545C→A, 746A→G, and 
776T→C) that are sufficient to cause deficient syn-
thesis of methylcobalamin. However, we specu-
late that these mutations allow for the formation 
of a modified protein with an intact functional 
domain for the synthesis of adenosylcobalamin.
The patients with combined homocystinuria 
and methylmalonic aciduria carry mutations 
(419dupA, 696+1_4del, and 748C→T) that are pre-
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dicted to lead to premature stop codons. We pre-
sume that these mutations would result either in 
a defective protein lacking both functional do-
mains or in a low, steady-state abundance of 
MMADHC mRNA by the mechanism of nonsense-
mediated mRNA decay.
These interpretations imply that at least two 
functional domains are present in the cblD pro-
tein and that the nature and location of the muta-
tions correlate with the biochemical phenotype. 
However, this hypothesis remains speculative until 
proved in more patients. An alternative hypothe-
sis is that even under normal conditions, two 
proteins are produced. However, we find no evi-
dence of two different transcripts, and a single 
transcript of MMADHC rescues both biochemical 
phenotypes. This gene can be added to the list 
of genes known to be associated with multiple 
phenotypes involving various subcellular com-
partments, such as the amnionless gene20 and 
the multiple sulfatase gene.21 To our knowledge, 
MMADHC is unique in that the three distinct bio-
chemical phenotypes involve both the cytosolic 
and mitochondrial pathways.
The protein sequence of MMADHC is highly 
conserved among various mammalian species 
(Fig. 3). MMADHC is not a member of any previ-
ously identified gene family but was initially se-
lected because of homology to a putative bacterial 
ABC transporter.
Although the segment of 91 amino acids be-
tween residues 78 and 168 shares 28% identity and 
46% similarity with a putative ATPase component 
of an ABC transporter from Salmonella enterica 
(YP_218380), the cblD protein lacks critical motifs 
of ABC transporters such as Walker A, Walker B, 
and an ABC signature.22 This makes it unlikely 
that the cblD protein is a classic ABC transporter. 
ABC transporters are a diverse family of proteins 
with multiple functions; MMADHC may be a new 
type of ABC transporter or may be involved in a 
complex that facilitates transport in a fashion 
similar to that of ABC transporters.
It is not known how cobalamin enters the mi-
tochondria in humans. Both active diffusion and 
passive diffusion have been suggested.23,24 In 
some bacteria, cobalamin transport is facilitated 
by two processes. First, it is transported through 
the outer membrane by the BtuB transporter,15 
which is mediated by TonB,25 a protein that cou-
ples energy from the proton motive force to the 
transport of cobalamin. Second, it is transported 
through the inner membrane by the BtuFCD ABC 
transport system.22 The C-terminal region of the 
human cblC protein (MMACHC) folds in a man-
ner similar to that of TonB from Escherichia coli,26 
and the human cblD protein MMADHC, the ex-
istence of which we have predicted, shares some 
sequence identity with an ABC transporter from 
S. enterica. It is tempting to speculate that the 
MMACHC and MMADHC genes may have evolved 
to carry out functional roles that are similar to 
those of their bacterial counterparts, by forming 
structurally similar proteins.
In conclusion, we studied seven patients with 
the cblD defect in vitamin B12 metabolism. We 
found that mutations in a gene we designated 
MMADHC are responsible for this defect, and we 
demonstrated that various mutations are associat-
ed with each of the three biochemical phenotypes 
of the disorder.
Figure 4 (facing page). Expression of Wild-Type and 
Mutant Alleles of Human MMADHC (Methylmalonic 
Aciduria, cblD Type, and Homocystinuria) in Immortal-
ized cblD-Combined, cblD-Homocystinuria, and Con-
trol Fibroblasts.
Cells from Patient 7 with the cblD-combined pheno-
type (homozygous for 696+1_4delGTGA), Patient 2 
with the cblD-homocystinuria phenotype (cblD-HC) 
(compound heterozygous for missense mutations 
545C→A and 746A→G), and one control were immortal-
ized and used for transfection experiments. Transient 
transfection was performed by means of electropora-
tion with pTracer (pTr) vectors containing an MMADHC 
allele: the wild-type allele, one of the three missense  
alleles (545C→A, 746A→G, or 776T→C) associated with 
cblD-HC, or the frame-shift deletion 57_64delCTCTTTAG 
or the nonsense mutation 160C→T associated with 
cblD–methylmalonic aciduria. Background activity was 
measured in cells transfected with empty pTracer vec-
tor (pTr only). Panel A shows the formation of methio-
nine from [14C]formate, and Panels B and C show the 
synthesis of methylcobalamin, and adenosylcobalamin, 
respectively, from [57Co]cyanocobalamin. Transfection 
of the cblD-combined cell line and the control cell  
line was also performed with the pcDNA3.2/V5 vector 
containing wild-type MMADHC. Background activity 
was measured in cells transfected with empty pcDNA3 
vector (pcDNA3.2 only). The data are means, and the  
I bars indicate the range of results of single determina-
tions from each experiment. For Panels A and B, the 
values are from three replicate experiments, and  
P values are shown only for comparisons indicating 
rescue of function. For Panel C, values for the pTracer 
vector are from seven replicate experiments, and those 
for the pcDNA3.2 vector are from three replicate ex-
periments.
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